Othair a bhfuil ceann agus ailse muineál ag fáil cóireáil groundbreaking nua a mbíonn i gceist leideanna a gcóras imdhíonachta cath leis an ngalar.
An triail, ag an An Institiúid Náisiúnta um Thaighde Sláinte lárionad taighde bithleighis i gColáiste Guy agus Naomh Tomás 'NHS iontaobhais bunús agus an Rí Londain, Baineann cealla bána fola othair géiniteach mhodhnú 'ionas aithníonn siad agus ionsaí ar an meall.
cealla bána fola ar an chóras imdhíonachta atá feistithe go nádúrtha chun cealla deireadh - go háirithe na cinn atá ionfhabhtaithe - nár cheart a bheith ann, ach uaireanta gá cuidiú a aithint agus cealla ailse ionsaí.
Ag baint úsáide as sampla fola, the BRC team is treating white blood cells in the laboratory with a harmless virus that introduces two new genes. The first gene makes it easier to grow the cells during their time in the laboratory while the second enables the white blood cells to recognise and attack the tumour.
Principal investigator Dr John Maher said: “In most cancers, metastasis, the spread of a disease from the part of the body where it started to another not directly connected, is the commonest cause of death. Mar sin féin, head and neck cancer is unusual in that local spread or recurrence of the disease accounts for most suffering and death. This means that tumours may become inoperable and do not shrink in response to traditional treatments such as chemotherapy or radiotherapy.”
The treatment is called a CAR T-cell and takes two weeks to produce. To maximise its safety and effectiveness the team is injecting the CAR T-cells directly into the tumour. CAR T-cell treatment has proven effective in some forms of leukaemia but the hope is that it can be developed further to benefit patients with so-called “solid cancers”, which form a discrete tumour mass, such as head and neck cancer.
Maher said success could have “significant implications for other solid cancers, especially those that spread within a natural space in the body, such as ovarian cancer (lining of the abdomen) or mesothelioma (lining of the lungs). In that setting, it may be possible to inject the CAR T-cells from the patient directly into the cavity, to localise the treatment where it is needed most”.
During the phase 1 trial, which aims to test the treatment’s safety and effectiveness, patients enrolled in groups will successively receive a higher number of cells to establish safe dosage, provided it does not produce significant side-effects. If it is successful, the treatment will need to be tested in larger numbers of patients to establish how effective it is at combating the cancer.
Dr Stephen Caddick, director of innovations at the Wellcome Trust, which co-funded the trial, Dúirt: “By precision engineering immune cells to recognise and destroy tumours, researchers are hopeful that they will be able to improve the prospects for patients who have, go dtí seo, faced very limited treatment options.”
guardian.co.uk © Caomhnóir Nuacht & Meáin Teoranta 2010